Opthea Ltd
NASDAQ:OPT

Watchlist Manager
Opthea Ltd Logo
Opthea Ltd
NASDAQ:OPT
Watchlist
Price: 3.41 USD 7.23% Market Closed
Market Cap: 306.7m USD

Operating Margin
Opthea Ltd

-623 532%
Current
-213 586.2%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-623 532%
=
Operating Profit
-155.9m
/
Revenue
25k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
AU
Opthea Ltd
ASX:OPT
820.8m AUD
-623 532%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
406.3B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.7B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
156.1B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.5B USD
28%
AU
CSL Ltd
ASX:CSL
83B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD
8%
NL
argenx SE
XBRU:ARGX
44B EUR
22%
No Stocks Found

Opthea Ltd
Glance View

Market Cap
306.7m USD
Industry
Biotechnology

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.

OPT Intrinsic Value
HIDDEN
Show
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-623 532%
=
Operating Profit
-155.9m
/
Revenue
25k
What is the Operating Margin of Opthea Ltd?

Based on Opthea Ltd's most recent financial statements, the company has Operating Margin of -623 532%.

Back to Top